Nostrum Biodiscovery joins Barcelona Science Park Blog Post

Nostrum Biodiscovery, a spin-off created thanks to the transfer of technology from the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center (BSC-CNS), has moved to Barcelona Science Park. Combining its own technologies with the best modelling software on the market, the company provides in silico services to pharmaceutical and biotechnology companies to accelerate and optimise the design of therapeutic molecules and enzymes, and overcome the common “bottlenecks” in the most initial stages of drug discovery.

 

A smartphone for detecting sleep apnea at home Blog Post

Researchers from the Institute for Bioengineering of Catalonia (IBEC) at the Barcelona Science Park (PCB) has developed a portable, cheap and non-invasive system to detect Obstructive Sleep Apnea (OSA) at home, a disorder characterized by recurrent airflow cessation during sleep. Researchers propose a novel method consisting of analyzing acoustic signals recorded with a smartphone.

 

The European biotechnology sector to meet in Hamburg Blog Post

Hamburg will host this year, from November 11 to 13, the 25th edition of BIO-Europe, the most important partnering event for the biotechnology and pharmaceutical industry in Europe, organized by EBD-Group. Biocat, the organization that coordinates and promotes the healthcare and life sciences sector in Catalonia, from its headquarters in the Barcelona Science Park (PCB), will be at the fair and help raise awareness of Catalan presence internationally. The event will feature, once again, an outstanding representation of the PCB Community.

 

Home stroke recovery thanks to virtual reality Blog Post

Today is the World Stroke Day, a medical condition that affects to 14.5 million people every year and it is the leading cause of death in women and the second cause in men. Health innovation contributes speeding up recovery of patients and it drastically reduces the number of visits to clinic as well as the duration of treatment in hospitals and therapy centres. It also reduces costs at the health public system. In these cases, technology can be a powerful ally, as can be seen from EIT Health Innovation Projects. EIT Health Spain, the Spanish Co-Location Center (CLC) of EIT Health, is headquartered at the Barcelona Science Park.

 

Scientists build machine learning-based algorithm to predict which cancer patients benefit from immunotherapy Blog Post

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park, in collaboration with the Centre for Genomic Regulation (CRG) and Radboud University, have built a tool that detects genetic mutations that trigger the immune system, helping identify which cancer patients are more likely to benefit from immunotherapy. The algorithm also reveals which people living with hereditary diseases may benefit from drugs that already exist. The new technology’s potential is described today in Nature Genetics.

 

The biotechnology company Aromics has been recognized as one of the most innovative Biotecs at the Sino-Europe Healthtech Innovation Week in China Blog Post

The Horizon 2020 project BERMES aimed to develop a novel therapy for malignant mesothelioma, lead by the catalan biotech company Aromics, was recognized as one of the most innovative initiatives at the Sino-Europe Innovation Week of Health Technology which was held from 12th to 16th October at two of the most technological and powerful cities in China: Nanjing and Shanghai. The biotechnology company, located at the Barcelona Science Park, participated in the event as part of a mission organized by the BioRegion of Catalonia to explore new opportunities for collaboration with Chinese companies and institutions and to learn about the experience of other European clusters in the Asian giant.

 

GlyCardial begins the clinical trial of its novel diagnostic device for myocardial ischemia Blog Post

GlyCardial Diagnostics, located at the Barcelona Science Park, has announced the enrolment of the first two patients in the EDICA trial: a multicenter international clinical study for the early detection of myocardial ischaemia. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), has developed innovative technology for the detection of Apo J-Glyc protein, as a novel biomarker in blood for the diagnosis and prognosis of myocardial ischemia, and expects to demonstrate the reliability of the new test in hospital laboratories.

 

New Born Solutions chosen to take part in the EIT Health Digital Sandbox Blog Post

New Born Solutions, based in the Barcelona Science Park (PCB), was one of the 10 small and medium-sized enterprises chosen to take part in the Digital Sandbox accelerator programme developed by EIT Health, the Knowledge and Innovation in Health Community, promoted by the European Institute of Innovation & Technology (EIT). The winning start-ups, chosen from around thirty applicants from all over Europe, will receive advisory services and up to €35,000 in funding to develop products and services making use of the data available on biobanks and quality registers in Europe.

 

IBEC obtains a second accreditation as Severo Ochoa Centre of Excellence Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park, is one of the six centres in Spain to be awarded accreditation in this round of the Severo Ochoa Excellence programme. Furthermore, IBEC is the only center that receives this accreditation for the second time. The awards last for four years and bring a million euros each year to the winning centres, it also implies strengthening research capacities and boosting success rates in other competitive funding programmes.

 

Biomarkers in blood for faster diagnosis: a new GAEM Accelerator project Blog Post

The GAEM Foundation, headquartered in Barcelona Science Park (PCB) and engaged in promoting biomedical research to cure multiple sclerosis, has added a study conducted by Institut d’Investigació Biomèdica de Girona (IDIBGI) to its Project Accelerator Programme. The objective of the study, led by Dr Jordi Tomàs Roig, is to discover new markers that enable us to predict a patient’s evolution from a simple blood test, while contributing to the design of epigenetic drugs to slow down the disease’s progression.